Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.12938 http://scihub22266oqcxt.onion/10.1111/ajt.12938 C4364523!4364523!25387592     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2014 ; 14 (12): 2685-90 Nephropedia Template TP {{tp|p=25387592|t=2014. Braking Bad: Novel Mechanisms of CTLA-4 Inhibition of T Cell Responses |pdf=|usr=}}{{25387592}} gab.com Text Braking Bad: Novel Mechanisms of CTLA-4 Inhibition of T Cell Responses JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=25387592 #FOAvip The coinhibitory receptor CTLA-4 is a master regulator of T cell responses and its function is critical in models of transplant tolerance. The CD28/CTLA-4 pathway is also an important therapeutic target, as the costimulation blocker belatacept was recently approved for use following renal transplantation. While the traditional model of CTLA-4 coinhibition focuses on its ability to directly counteract CD28 costimulation, recently this paradigm has significantly broadened. Recent work has uncovered the ability of CTLA-4 to act as a cell-extrinsic coinhibitory molecule on CD4+ T cell effectors. While it has been appreciated that CTLA-4 is required FoxP3+ Treg suppression, current studies have elucidated important differences in the function of CTLA-4 on Tregs compared to effectors. CTLA-4 expression patterns also differ by T cell subsets, with Th17 cells expressing significantly higher levels of CTLA-4. Thus, in contrast to the traditional model of CTLA-4 as a negative receptor to counter CD28 costimulation, recent work has begun to define CTLA-4 as a global regulator of T cell responses with subset-specific functions. Future studies must continue to uncover the molecular mechanisms that govern CTLA-4 function. These novel findings have implications for novel strategies to maximize the regulatory potential of CTLA-4 during allogeneic T cell responses. Twit Text FOAVip Braking Bad: Novel Mechanisms of CTLA-4 Inhibition of T Cell Responses ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=25387592 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25387592 #FOAvip English Wikipedia <ref>{{Cite pmid|25387592}}</ref> Braking Bad: Novel Mechanisms of CTLA-4 Inhibition of T Cell Responses #MMPMID25387592 Krummey SM; Ford ML Am J Transplant 2014[Dec]; 14 (12): 2685-90 PMID25387592show ga The coinhibitory receptor CTLA-4 is a master regulator of T cell responses and its function is critical in models of transplant tolerance. The CD28/CTLA-4 pathway is also an important therapeutic target, as the costimulation blocker belatacept was recently approved for use following renal transplantation. While the traditional model of CTLA-4 coinhibition focuses on its ability to directly counteract CD28 costimulation, recently this paradigm has significantly broadened. Recent work has uncovered the ability of CTLA-4 to act as a cell-extrinsic coinhibitory molecule on CD4+ T cell effectors. While it has been appreciated that CTLA-4 is required FoxP3+ Treg suppression, current studies have elucidated important differences in the function of CTLA-4 on Tregs compared to effectors. CTLA-4 expression patterns also differ by T cell subsets, with Th17 cells expressing significantly higher levels of CTLA-4. Thus, in contrast to the traditional model of CTLA-4 as a negative receptor to counter CD28 costimulation, recent work has begun to define CTLA-4 as a global regulator of T cell responses with subset-specific functions. Future studies must continue to uncover the molecular mechanisms that govern CTLA-4 function. These novel findings have implications for novel strategies to maximize the regulatory potential of CTLA-4 during allogeneic T cell responses. äBraking Bad: Novel Mechanisms of CTLA-4 Inhibition of T Cell Responses(epmc).pdf DeepDyve Pubget Overpricing